Search

Your search keyword '"Pei, Qinglin"' showing total 198 results
Start Over Author "Pei, Qinglin"
198 results on '"Pei, Qinglin"'

1. An evaluation of machine learning techniques to predict the outcome of children treated for Hodgkin-Lymphoma on the AHOD0031 trial: A report from the Children's Oncology Group

Author

Beaulac, Cédric, Rosenthal, Jeffrey S., Pei, Qinglin, Friedman, Debra, Wolden, Suzanne, and Hodgson, David

Subjects
Quantitative Biology - Quantitative Methods, Statistics - Applications, Statistics - Machine Learning
Abstract

In this manuscript we analyze a data set containing information on children with Hodgkin Lymphoma (HL) enrolled on a clinical trial. Treatments received and survival status were collected together with other covariates such as demographics and clinical measurements. Our main task is to explore the potential of machine learning (ML) algorithms in a survival analysis context in order to improve over the Cox Proportional Hazard (CoxPH) model. We discuss the weaknesses of the CoxPH model we would like to improve upon and then we introduce multiple algorithms, from well-established ones to state-of-the-art models, that solve these issues. We then compare every model according to the concordance index and the brier score. Finally, we produce a series of recommendations, based on our experience, for practitioners that would like to benefit from the recent advances in artificial intelligence.

Published
2020
Full Text
View/download PDF

2. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy

Author

Hoppe, Bradford S., McCarten, Kathleen M., Pei, Qinglin, Kessel, Sandy, Alazraki, Adina, Mhlanga, Joyce C., Lai, Hollie A., Eutsler, Eric, Hodgson, David C., Roberts, Kenneth B., Charpentier, Anne-Marie, Keller, Frank G., Voss, Stephan D., Wu, Yue, Cho, Steve Y., Kelly, Kara M., and Castellino, Sharon M.

Published
2023
Full Text
View/download PDF

6. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study

Author

Dvorak, Christopher C, Satwani, Prakash, Stieglitz, Elliot, Cairo, Mitchell S, Dang, Ha, Pei, Qinglin, Gao, Yun, Wall, Donna, Mazor, Tali, Olshen, Adam B, Parker, Joel S, Kahwash, Samir, Hirsch, Betsy, Raimondi, Susana, Patel, Neil, Skeens, Micah, Cooper, Todd, Mehta, Parinda A, Grupp, Stephan A, and Loh, Mignon L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Childhood Leukemia, Genetics, Transplantation, Cancer, Rare Diseases, Pediatric, Clinical Research, Hematology, Pediatric Cancer, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Busulfan, Child, Child, Preschool, Female, Follow-Up Studies, Graft Rejection, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Infant, Infant, Newborn, Leukemia, Myelomonocytic, Juvenile, Male, Myeloablative Agonists, Prognosis, Transplantation Conditioning, Vidarabine, conditioning regimens, hematopoietic cell transplantation, juvenile myelomonocytic leukemia, mutant allele burden, Clinical Sciences, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis, Paediatrics
Abstract

BackgroundMost patients with juvenile myelomonocytic leukemia (JMML) are curable only with allogeneic hematopoietic cell transplantation (HCT). However, the current standard conditioning regimen, busulfan-cyclophosphamide-melphalan (Bu-Cy-Mel), may be associated with higher risks of morbidity and mortality. ASCT1221 was designed to test whether the potentially less-toxic myeloablative conditioning regimen containing busulfan-fludarabine (Bu-Flu) would be associated with equivalent outcomes.ProcedureTwenty-seven patients were enrolled on ASCT1221 from 2013 to 2015. Pre- and post-HCT (starting Day +30) mutant allele burden was measured in all and pre-HCT therapy was administered according to physician discretion.ResultsFifteen patients were randomized (six to Bu-Cy-Mel and nine to Bu-Flu) after meeting diagnostic criteria for JMML. Pre-HCT low-dose chemotherapy did not appear to reduce pre-HCT disease burden. Two patients, however, received aggressive chemotherapy pre-HCT and achieved low disease-burden state; both are long-term survivors. All four patients with detectable mutant allele burden at Day +30 post-HCT eventually progressed compared to two of nine patients with unmeasurable allele burden (P = 0.04). The 18-month event-free survival of the entire cohort was 47% (95% CI, 21-69%), and was 83% (95% CI, 27-97%) and 22% (95% CI, 03-51%) for Bu-Cy-Mel and Bu-Flu, respectively (P = 0.04). ASCT1221 was terminated early due to concerns that the Bu-Flu arm had inferior outcomes.ConclusionsThe regimen of Bu-Flu is inadequate to provide disease control in patients with JMML who present to HCT with large burdens of disease. Advances in molecular testing may allow better characterization of biologic risk, pre-HCT responses to chemotherapy, and post-HCT management.

Published
2018

7. Locomotor Training and Strength and Balance Exercises for Walking Recovery After Stroke: Response to Number of Training Sessions

Author

Rose, Dorian K, Nadeau, Stephen E, Wu, Samuel S, Tilson, Julie K, Dobkin, Bruce H, Pei, Qinglin, and Duncan, Pamela W

Subjects
Clinical Research, Physical Rehabilitation, Stroke, Aging, Brain Disorders, Rehabilitation, Clinical Trials and Supportive Activities, 6.7 Physical, Evaluation of treatments and therapeutic interventions, Aged, Female, Humans, Male, Middle Aged, Postural Balance, Recovery of Function, Resistance Training, Single-Blind Method, Stroke Rehabilitation, Treatment Outcome, Walking, Walking Speed, Clinical Sciences, Human Movement and Sports Sciences
Abstract

BackgroundEvidence-based guidelines are needed to inform rehabilitation practice, including the effect of number of exercise training sessions on recovery of walking ability after stroke.ObjectiveThe objective of this study was to determine the response to increasing number of training sessions of 2 interventions-locomotor training and strength and balance exercises-on poststroke walking recovery.DesignThis is a secondary analysis of the Locomotor Experience Applied Post-Stroke (LEAPS) randomized controlled trial.SettingSix rehabilitation sites in California and Florida and participants' homes were used.ParticipantsParticipants were adults who dwelled in the community (N=347), had had a stroke, were able to walk at least 3 m (10 ft) with assistance, and had completed the required number of intervention sessions.InterventionParticipants received 36 sessions (3 times per week for 12 weeks), 90 minutes in duration, of locomotor training (gait training on a treadmill with body-weight support and overground training) or strength and balance training.MeasurementsTalking speed, as measured by the 10-Meter Walk Test, and 6-minute walking distance were assessed before training and following 12, 24, and 36 intervention sessions.ResultsParticipants at 2 and 6 months after stroke gained in gait speed and walking endurance after up to 36 sessions of treatment, but the rate of gain diminished steadily and, on average, was very low during the 25- to 36-session epoch, regardless of treatment type or severity of impairment.LimitationsResults may not generalize to people who are unable to initiate a step at 2 months after stroke or people with severe cardiac disease.ConclusionsIn general, people who dwelled in the community showed improvements in gait speed and walking distance with up to 36 sessions of locomotor training or strength and balance exercises at both 2 and 6 months after stroke. However, gains beyond 24 sessions tended to be very modest. The tracking of individual response trajectories is imperative in planning treatment.

Published
2017

8. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

Author

Lo, Andrea C., primary, Liu, Amy, additional, Liu, Qi, additional, Yasui, Yutaka, additional, Castellino, Sharon M., additional, Kelly, Kara M., additional, Hererra, Alex F., additional, Friedberg, Jonathan W., additional, Friedman, Debra L., additional, Schwartz, Cindy L., additional, Pei, Qinglin, additional, Kessel, Sandy, additional, Bergeron-Gravel, Samuel, additional, Dama, Hitesh, additional, Roberts, Kenneth, additional, Constine, Louis S., additional, and Hodgson, David C., additional

Published
2024
Full Text
View/download PDF

10. Accelerating pediatric Hodgkin lymphoma research: the Hodgkin Lymphoma Data Collaboration (NODAL).

Author

Wyatt, Kirk D, Birz, Suzi, Castellino, Sharon M, Henderson, Tara O, Lucas, John T, Pei, Qinglin, Zhou, Yiwang, Volchenboum, Samuel L, Furner, Brian, Watkins, Michael, Kelly, Kara M, Flerlage, Jamie E, and (NODAL), the Hodgkin Lymphoma Data Collaboration

Subjects
CHILDHOOD cancer, HODGKIN'S disease, INFORMATION technology, CONSORTIA, INFORMATION sharing
Abstract

Data commons have proven to be an indispensable avenue for advancing pediatric cancer research by serving as unified information technology platforms that, when coupled with data standards, facilitate data sharing. The Pediatric Cancer Data Commons, the flagship project of Data for the Common Good (D4CG), collaborates with disease-based consortia to facilitate development of clinical data standards, harmonization and pooling of clinical data from disparate sources, establishment of governance structure, and sharing of clinical data. In the interest of international collaboration, researchers developed the Hodgkin Lymphoma Data Collaboration and forged a relationship with the Pediatric Cancer Data Commons to establish a data commons for pediatric Hodgkin lymphoma. Herein, we describe the progress made in the formation of Hodgkin Lymphoma Data Collaboration and foundational goals to advance pediatric Hodgkin lymphoma research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. The Effects of Stroke Type, Locus, and Extent on Long-Term Outcome of Gait Rehabilitation

Author

Nadeau, Stephen E, Dobkin, Bruce, Wu, Samuel S, Pei, Qinglin, Duncan, Pamela W, and Team, for the LEAPS Investigative

Subjects
Biomedical and Clinical Sciences, Neurosciences, Brain Disorders, Rehabilitation, Aging, Stroke, Adult, Female, Functional Laterality, Gait Disorders, Neurologic, Humans, Locomotion, Longitudinal Studies, Magnetic Resonance Imaging, Male, Physical Therapy Modalities, Recovery of Function, Regression Analysis, Single-Blind Method, Young Adult, LEAPS Investigative Team, gait, hemiparesis, lesion locus, rehabilitation, stroke, Clinical Sciences, Cognitive Sciences
Abstract

Background Paresis in stroke is largely a result of damage to descending corticospinal and corticobulbar pathways. Recovery of paresis predominantly reflects the impact on the neural consequences of this white matter lesion by reactive neuroplasticity (mechanisms involved in spontaneous recovery) and experience-dependent neuroplasticity, driven by therapy and daily experience. However, both theoretical considerations and empirical data suggest that type of stroke (large vessel distribution/lacunar infarction, hemorrhage), locus and extent of infarction (basal ganglia, right-hemisphere cerebral cortex), and the presence of leukoaraiosis or prior stroke might influence long-term recovery of walking ability. In this secondary analysis based on the 408 participants in the Locomotor Experience Applied Post-Stroke (LEAPS) study database, we seek to address these possibilities. Methods Lesion type, locus, and extent were characterized by the 2 neurologists in the LEAPS trial on the basis of clinical computed tomography and magnetic resonance imaging scans. A series of regression models was used to test our hypotheses regarding the effects of lesion type, locus, extent, and laterality on 2- to 12-month change in gait speed, controlling for baseline gait speed, age, and Berg Balance Scale score. Results Gait speed change at 1 year was significantly reduced in participants with basal ganglia involvement and prior stroke. There was a trend toward reduction of gait speed change in participants with lacunar infarctions. The presence of right-hemisphere cortical involvement had no significant impact on outcome. Conclusions Type, locus, and extent of lesion, and the loss of substrate for neuroplastic effect as a result of prior stroke may affect long-term outcome of rehabilitation of hemiparetic gait.

Published
2016

12. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group AHOD 1331 study

Author

Parsons, Susan K., primary, Rodday, Angie Mae, additional, Pei, Qinglin, additional, Keller, Frank G., additional, Wu, Yue, additional, Henderson, Tara O., additional, Cella, David, additional, Kelly, Kara M., additional, and Castellino, Sharon M., additional

Published
2023
Full Text
View/download PDF

13. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031

Author

Parzuchowski, Aaron, Bush, Rizvan, Pei, Qinglin, Friedman, Debra L., FitzGerald, Thomas J., Wolden, Suzanne L., Dharmarajan, Kavita V., Constine, Louis S., Laurie, Fran, Kessel, Sandy K., Appel, Burton, Fernandez, Karen, Punnett, Angela, Schwartz, Cindy L., Cox, Jacob, and Terezakis, Stephanie A.

Published
2018
Full Text
View/download PDF

15. Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831

Author

Lo, Andrea C., primary, Lee, Inki, additional, Pei, Qinglin, additional, Wu, Yue, additional, McCarten, Kathleen M., additional, Hoppe, Bradford S., additional, Hodgson, David C., additional, Roberts, Kenneth, additional, Milgrom, Sarah, additional, Kessel, Sandy, additional, Cole, Peter D., additional, Kelly, Kara M., additional, and Cho, Steve Y., additional

Published
2023
Full Text
View/download PDF

17. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study

Author

Milgrom, Sarah A., primary, Kim, Jihyun, additional, Pei, Qinglin, additional, Lee, Inki, additional, Hoppe, Bradford S., additional, Wu, Yue, additional, Hodgson, David, additional, Kessel, Sandy, additional, McCarten, Kathleen M., additional, Roberts, Kenneth, additional, Lo, Andrea C., additional, Cole, Peter D., additional, Kelly, Kara M., additional, and Cho, Steve Y., additional

Published
2023
Full Text
View/download PDF

18. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using PET Response−Adapted Radiotherapy

Author

Hoppe, Bradford S., primary, McCarten, Kathleen M., additional, Pei, Qinglin, additional, Kessel, Sandy, additional, Alazraki, Adina, additional, Mhlanga, Joyce C., additional, Lai, Hollie A., additional, Eutsler, Eric, additional, Hodgson, David C., additional, Roberts, Kenneth B., additional, Charpentier, Anne-Marie, additional, Keller, Frank G., additional, Voss, Stephan D., additional, Wu, Yue, additional, Cho, Steve Y., additional, Kelly, Kara M., additional, and Castellino, Sharon M., additional

Published
2023
Full Text
View/download PDF

21. Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children's Oncology Group (COG) AHOD1331 Study

Author

Parsons, Susan K., primary, Keller, Frank G., additional, Pei, Qinglin, additional, Rodday, Angie Mae, additional, Belsky, Jennifer, additional, Wu, Yue, additional, Punnett, Angela, additional, Henderson, Tara O, additional, Kelly, Kara M., additional, and Castellino, Sharon M., additional

Published
2022
Full Text
View/download PDF

23. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Author

Castellino, Sharon M., primary, Pei, Qinglin, additional, Parsons, Susan K., additional, Hodgson, David, additional, McCarten, Kathleen, additional, Horton, Terzah, additional, Cho, Steve, additional, Wu, Yue, additional, Punnett, Angela, additional, Dave, Hema, additional, Henderson, Tara O., additional, Hoppe, Bradford S., additional, Charpentier, Anne-Marie, additional, Keller, Frank G., additional, and Kelly, Kara M., additional

Published
2022
Full Text
View/download PDF

24. T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma

Author

Castellino, Sharon M., primary, Pei, Qinglin, additional, Parsons, Susan K., additional, Hodgson, David, additional, Mccarten, Kathleen, additional, Horton, Terzah, additional, Cho, Steve, additional, Wu, Yue, additional, Punnett, Angela, additional, Dave, Hema, additional, Henderson, Tara O., additional, Hoppe, Bradford S., additional, Charpentier, Ann-Marie, additional, Keller, Frank G., additional, and Kelly, Kara M., additional

Published
2022
Full Text
View/download PDF

25. P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL

Author

Flerlage, Jamie E., primary, Birz, Suzi, additional, Castellino, Sharon M., additional, Appel, Burton, additional, Furner, Brian, additional, Graglia, Luca, additional, Henderson, Tara O., additional, Hodgson, David, additional, Hoppe, Bradford S., additional, Kahn, Justine, additional, Keller, Frank G., additional, Kessel, Sandy, additional, Li, Chen, additional, Li, Mei, additional, Lucas, John, additional, Mccarten, Kathleen, additional, Metzger, Monika, additional, Milgrom, Sarah, additional, Parsons, Susan K., additional, Pei, Qinglin, additional, Wu, Yue, additional, Zhou, Yiwang, additional, Watkins, Michael, additional, Volchenbaum, Sam, additional, and Kelly, Kara M., additional

Published
2022
Full Text
View/download PDF

26. Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463).

Author

Castellino, Sharon M., primary, Pei, Qinglin, additional, Parsons, Susan K., additional, Hodgson, David C., additional, McCarten, Kathleen, additional, Punnett, Angela, additional, Horton, Terzah M., additional, Dave, Hema Kishore, additional, Cho, Steve Y., additional, Wu, Yue, additional, Henderson, Tara O., additional, Hoppe, Bradford, additional, Keller, Frank G., additional, and Kelly, Kara, additional

Published
2022
Full Text
View/download PDF

27. Durable remission for four pediatric patients with high‐risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group

Author

Buhtoiarov, Ilia N., primary, Mba, Nkechi I., additional, Santos, Crystal D. L., additional, McCarten, Kathleen M., additional, Metzger, Monika L., additional, Pei, Qinglin, additional, Bush, Rizvan, additional, Baker, Kayla, additional, Kelly, Kara M., additional, and Cole, Peter D., additional

Published
2022
Full Text
View/download PDF

28. Evaluating Disparities in Proton Radiation Therapy Use in a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma

Author

Mailhot Vega, Raymond B., primary, Castellino, Sharon M., additional, Pei, Qinglin, additional, Parsons, Susan, additional, Roberts, Kenneth B., additional, Hodgson, David, additional, Charpentier, Anne-Marie, additional, Fitzgerald, Thomas J., additional, Kessel, Sandy K., additional, Keller, Frank G., additional, Kelly, Kara, additional, and Hoppe, Bradford S., additional

Published
2021
Full Text
View/download PDF

30. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate‐risk Hodgkin lymphoma treated with chemo‐radiation therapy: FDG‐PET parameter analysis in a subgroup from COG AHOD0031

Author

Milgrom, Sarah A., primary, Kim, Jihyun, additional, Chirindel, Alin, additional, Kim, Jongho, additional, Pei, Qinglin, additional, Chen, Lu, additional, Buxton, Allen, additional, Kessel, Sandy, additional, Leal, Jeffrey, additional, McCarten, Kathleen M., additional, Hoppe, Bradford S., additional, Wolden, Suzanne L., additional, Schwartz, Cindy L., additional, Friedman, Debra L., additional, Kelly, Kara M., additional, and Cho, Steve Y., additional

Published
2021
Full Text
View/download PDF

33. Survival Differs by Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group

Author

Kahn, Justine M., primary, Pei, Qinglin, additional, Friedman, Debra L., additional, Kaplan, Joel, additional, Keller, Frank G., additional, Hodgson, David, additional, Wu, Yue, additional, Appel, Burton E., additional, Bhatia, Smita, additional, Henderson, Tara O., additional, Schwartz, Cindy L., additional, Kelly, Kara M., additional, and Castellino, Sharon M., additional

Published
2021
Full Text
View/download PDF

34. Survival Varies By Age and Histology in Classical Hodgkin Lymphoma: A Report from the Children's Oncology Group

Author

Kahn, Justine M., primary, Kelly, Kara M., additional, Pei, Qinglin, additional, Wu, Yue, additional, Friedman, Debra L., additional, Henderson, Tara O., additional, Hodgson, David C., additional, Kaplan, Joel A., additional, Keller, Frank G., additional, Bhatia, Smita, additional, Schwartz, Cindy L., additional, and Castellino, Sharon M., additional

Published
2020
Full Text
View/download PDF

35. Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331

Author

Dave, Hema, primary, Mai, Mimi, additional, Datar, Anushree, additional, Jenkins, Gaye, additional, Pei, Qinglin, additional, Wu, Yue, additional, Keller, Frank G., additional, Castellino, Sharon M., additional, Horton, Terzah M, additional, and Bollard, Catherine M., additional

Published
2020
Full Text
View/download PDF

38. Abstract IA37: Survival by race and ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A report from the Children’s Oncology Group

Author

Kahn, Justine, primary, Kelly, Kara M., additional, Pei, Qinglin, additional, Bush, Rizvan, additional, Friedman, Debra L., additional, Keller, Frank G., additional, Bhatia, Smita, additional, Henderson, Tara O., additional, Schwartz, Cindy L., additional, and Castellino, Sharon M., additional

Published
2020
Full Text
View/download PDF

44. LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.

Author

Moerdler, Scott, Ewart, Michelle, Friedman, Debra L., Kelly, Kara, Pei, Qinglin, Peng, Mou, Zang, XingXing, and Cole, Peter D.

Subjects
HODGKIN'S disease, LYMPHOCYTES, INHIBITION of cellular proliferation, CELL physiology, T cells, CHILDHOOD cancer, CANCER prognosis, PROTEIN expression, PROGRAMMED death-ligand 1
Abstract

LAG-3, through interaction with a variety of ligands, regulates T cell function via inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children's Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

Author

Cole, Peter D, primary, McCarten, Kathleen M, additional, Pei, Qinglin, additional, Spira, Menachem, additional, Metzger, Monika L, additional, Drachtman, Richard A, additional, Horton, Terzah M, additional, Bush, Rizvan, additional, Blaney, Susan M, additional, Weigel, Brenda J, additional, and Kelly, Kara M, additional

Published
2018
Full Text
View/download PDF

48. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group

Author

Keller, Frank G., primary, Castellino, Sharon M., additional, Chen, Lu, additional, Pei, Qinglin, additional, Voss, Stephan D., additional, McCarten, Kathleen M., additional, Senn, Stacy L., additional, Buxton, Allen B., additional, Bush, Rizvan, additional, Constine, Louis S., additional, and Schwartz, Cindy L., additional

Published
2018
Full Text
View/download PDF

49. Regional variation in post-stroke multidisciplinary rehabilitation care among veteran residents in community nursing homes

Author

Jia,Huanguang, Pei,Qinglin, Sullivan,Charles, Cowper Ripley,Diane, Wu,Samuel, Vogel,W, Wang,Xinping, Bidelspach,Douglas, Hale-Gallardo,Jennifer, Bates,Barbara, Jia,Huanguang, Pei,Qinglin, Sullivan,Charles, Cowper Ripley,Diane, Wu,Samuel, Vogel,W, Wang,Xinping, Bidelspach,Douglas, Hale-Gallardo,Jennifer, and Bates,Barbara

Abstract

Huanguang Jia,1 Qinglin Pei,1 Charles T Sullivan,1 Diane C Cowper Ripley,1 Samuel S Wu,1 W Bruce Vogel,1 Xinping Wang,1 Douglas E Bidelspach,2 Jennifer L Hale-Gallardo,1 Barbara E Bates3 1Center of Innovation on Disability and Rehabilitation Research, North Florida/South Georgia Veterans Health System, Gainesville, FL, 2Physical Medicine and Rehabilitation Service, Department of Veterans Affairs, Washington, DC, 3Aleda E. Lutz VA Medical Center, Saginaw, MI, USA Introduction: Effective post-acute multidisciplinary rehabilitation therapy improves stroke survivors’ functional recovery and daily living activities. The US Department of Veterans Affairs (VA) places veterans needing post-acute institutional care in private community nursing homes (CNHs). These placements are made under the same rules and regulations across the VA health care system and through individual per diem contracts between local VA facilities and CNHs. However, there is limited information about utilization of these veterans’ health services as well as the geographic variation of the service utilization. Aim: The aims of this study were to determine rehabilitation therapy and restorative nursing care utilization by veterans with stroke in VA-contracted CNHs and to assess risk-adjusted regional variations in the utilization of rehabilitation therapy and restorative nursing care. Methods: This retrospective study included all veterans diagnosed with stroke residing in VA-contracted CNHs between 2006 and 2009. Minimum Dataset (a health status assessment tool for CNH residents) for the study CNHs was linked with veterans’ inpatient and outpatient data within the VA health care system. CNHs were grouped into five VA-defined geographic regions: the North Atlantic, Southeast, Midwest, Continental, and Pacific regions. A two-part model was applied estimating risk-adjusted utilization probability and average weekly utilization days. Two dependent variables were rehabilitation

Published
2017

50. Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group

Author

Untanu, Ramona Vesna, primary, Back, Jason, additional, Appel, Burton, additional, Pei, Qinglin, additional, Chen, Lu, additional, Buxton, Allen, additional, Hodgson, David C., additional, Ehrlich, Peter F., additional, Constine, Louis S., additional, Schwartz, Cindy L., additional, and Hutchison, Robert E., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results